Palatin Obtains Imaging Agent Approval, Aims For General Infection Nod
This article was originally published in The Gray Sheet
Executive Summary
Palatin/Mallinckrodt's NeutroSpec imaging agent will be available in mid-August, following FDA approval July 2 for diagnosing equivocal appendicitis in patients aged five years and older with atypical symptoms
You may also be interested in...
Palatin's LeuTech Clinically Useful For Appendicitis Diagnosis - FDA Panel
Clinical management decisions on whether to use computed tomography (CT) or Palatin's LeuTech imaging agent for detecting appendicitis in patients with equivocal appendicitis likely will depend on an institution's level of expertise with each modality.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.